首页|恩格列净对2型糖尿病患者血糖水平及胰岛素抵抗的影响

恩格列净对2型糖尿病患者血糖水平及胰岛素抵抗的影响

扫码查看
目的 研究恩格列净对2型糖尿病患者血糖水平及胰岛素抵抗的影响.方法 选取2020年4月-2023年4月在我院诊治的72例2型糖尿病患者为研究对象,采用随机数字表法分为对照组(n=36)和观察组(n=36),对照组采用盐酸二甲双胍片治疗,观察组在对照组基础上给予恩格列净治疗,比较两组临床疗效、血糖指标[空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)]、胰岛素抵抗指数(HOMA-IR)、空腹胰岛素(FIns)、血脂指标[总胆固醇(TC)、三酰甘油(TG)]、不良反应发生率.结果 观察组治疗总有效率为94.44%,高于对照组的83.33%(P<0.05);两组FPG、2hPG、HbA1c均低于治疗前,且观察组低于对照组(P<0.05);两组HOMA-IR均低于治疗前,FIns均高于治疗前,且观察组HOMA-IR低于对照组,FIns高于对照组(P<0.05);两组TC、TG均低于治疗前,且观察组低于对照组(P<0.05);观察组不良反应发生率为5.56%,低于对照组的13.89%(P<0.05).结论 恩格列净治疗2型糖尿病疗效确切,可促进血糖水平控制,降低胰岛素抵抗,改善血脂指标水平,且可降低不良反应发生率,是一种有效、安全的药物,值得临床应用.
Effect of Empagliflozin on Blood Glucose Level and Insulin Resistance in Patients with Type 2 Diabetes Mellitus
Objective To study the effect of empagliflozin on blood glucose level and insulin resistance in patients with type 2 diabetes mellitus.Methods A total of 72 patients with type 2 diabetes ellitus who were diagnosed and treated in our hospital from April 2020 to April 2023 were selected as the research objects.They were divided into control group(n=36)and observation group(n=36)by random number table method.The control group was treated with metformin hydrochloride tablets,and the observation group was treated with empagliflozin on the basis of the control group.The clinical efficacy,blood glucose indexes[fasting blood glucose(FPG),2-h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c)],insulin resistance index(HOMA-IR),fasting insulin(FIns),blood lipid indexes[total cholesterol(TC),triglyceride(TG)]and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.44%,which was higher than 83.33%in the control group(P<0.05).FPG,2hPG and HbA1c in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).HOMA-IR in the two groups was lower than that before treatment,FIns was higher than that before treatment,and HOMA-IR in the observation group was lower than that in the control group,FIns was higher than that in the control group(P<0.05).TC and TG in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was 5.56%,which was lower than 13.89%in the control group(P<0.05).Conclusion Empagliflozin is effective in the treatment of type 2 diabetes mellitus,which can promote the control of blood glucose level,reduce insulin resistance,improve blood lipid index level,and reduce the incidence of adverse reactions.It is an effective and safe drug,which is worthy of clinical application.

EmpagliflozinType 2 diabetes mellitusBlood glucose levelInsulin resistance

陈金华

展开 >

鹰潭市余江区人民医院内一科,江西鹰潭 335200

恩格列净 2型糖尿病 血糖水平 胰岛素抵抗

2024

医学信息
国家卫生部信息化管理领导小组 中国电子学会中国医药信息学分会 陕西文博生物信息工程研究所

医学信息

影响因子:0.161
ISSN:1006-1959
年,卷(期):2024.37(18)